Table 2.

Selected biased agonists under different phases of evaluation for therapeutic use.

Ligand	Receptor	Signalling bias	Indication	Development status
Carvedilol	Beta 1 AR Beta 2 AR	Mild βarrestin	Congestive heart failure	Approved
Oliceridine (TRV130)	Mu opioid	G protein	Moderate to severe pain	Phase III
TRV734	Mu opioid	G protein	Moderate to severe pain	Phase I
Triazole 1.1	Kappa opioid	G protein	Pruritus	Preclinical
RB-64	Kappa opioid	G protein	Pain	Preclinical
PZM21	Mu opioid	G protein	Pain	Preclinical
UNC9994, UNC9975	Dopamine 2	βarrestin	Schizophrenia and mood disorders	Preclinical
TRV250	Delta opioid	G protein	Migraine	Preclinical